Micron Biomedical Inc.
575 Fourteenth Street, NW
Suite 100
Atlanta
Georgia
30318
United States
Website: http://micronbiomedical.com/
Email: info@micronbiomedical.com
About Micron Biomedical Inc.
Micron develops pharmaceutical products, based on its proprietary microneedle patch technology, that are designed to provide enhanced vaccines and proprietary drugs efficacy, superior patient compliance, and simplified administration, distribution, and storage logistics.YEAR FOUNDED:
August 2014
LEADERSHIP:
Co-Founder, CEO & CSO: Mark Prausnitz, PhD
CBO: Arvinder Singh
Co-Founder & VP, R&D: Devin McAllister, PhD
Co-Founder & VP, Program Management: Sebastien Henry, MS, MBA
9 articles about Micron Biomedical Inc.
-
Micron Biomedical Appoints Global Health Pioneer and Champion of Vaccine Access, Dr. Seth Berkley, as Scientific Advisor to the CEO
2/27/2024
Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, announced the appointment of global public health pioneer, Dr. Seth Berkley, as scientific advisor to the CEO.
-
Micron Biomedical Receives $23.6 Million to Accelerate Commercial Manufacturing of Needle-Free Vaccines and to Help Eradicate Measles
11/16/2023
Micron Biomedical announced a $23.6 million grant from the Bill & Melinda Gates Foundation that will fund mass production of needle-free vaccines.
-
Micron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of Directors
8/9/2023
Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the administration, transport and storage of drugs and vaccines, today announced the appointment of drug delivery and healthcare innovation veteran, Brian Bernick, MD, as Chairman of the company's Board of Directors.
-
Micron Biomedical Extends Series A to $17 Million to Bring Needle-Free Drugs and Vaccines to Market
5/10/2023
Micron Biomedical announced it has secured an additional $3 million investment from J2 Ventures, bringing its total Series A funding to $17 million.
-
Micron Biomedical Secures Series A Financing to Commercialize MAP Technology for Self-Administration of Drugs and Vaccines without Needles
11/28/2022
Micron Biomedical, Inc. secures a $14 million Series A financing will support the company's development of commercial manufacturing, currently underway and establishes a strong partnership between Micron and LTS Lohmann.
-
Micron Biomedical Initiates First-Ever Microneedle Vaccine Clinical Trial in Children
7/13/2021
– Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron's Microneedle-Based Measles-Rubella Vaccine –
-
Micron Biomedical Progresses with Clinical Evaluation of Its Technology for Measles-Rubella Vaccination
9/1/2020
Micron Biomedical, Inc. (Micron) recently received a second tranche of funding ($2.6M) to continue clinical development of its microneedle-based technology for measles and rubella vaccination from the Bill & Melinda Gates Foundation.
-
Steven Damon Appointed Chief Executive Officer of Micron Biomedical, A Novel Vaccine and Therapeutic Technology Company
6/1/2020
Micron Biomedical, Inc., an Atlanta based biopharmaceutical company, has appointed industry veteran, Steven Damon , as the company CEO. Mr. Damon will lead Micron on a path to rapid development and commercialization of Micron's proprietary dissolvable, microneedle-based technology, a novel technology designed for simple, safe and effective
-
Micron Biomedical Release: Phase I Clinical Trial Shows Safety And Immunogenicity Of Microneedle Patch For Flu Vaccination For The First Time
6/28/2017